Microprotein, macro-effect: DWORF as a therapeutic strategy in heart failure

Area of Science:

• Cardiology
• Molecular Biology
• Biochemistry

Background:

• Heart failure (HF) is a major global health issue with significant morbidity and mortality.
• Impaired sarcoplasmic reticulum (SR) Ca²⁺ cycling, due to reduced SR Ca²⁺-ATPase 2a (SERCA2a) activity, is a key feature of HF.
• Current therapies for HF have limitations, and targeting SERCA2a regulators like phospholamban (PLN) presents safety concerns.

Purpose of the Study:

• To review the molecular mechanisms of Dwarf Open Reading Frame (DWORF), a positive regulator of SERCA2a.
• To evaluate the therapeutic potential of DWORF gene therapy in preclinical models of heart failure.
• To discuss translational considerations for advancing DWORF-based therapies for HF.

Main Methods:

• Review of existing literature on DWORF, SERCA2a, and phospholamban (PLN).
• Analysis of preclinical data from various HF models (e.g., dilated cardiomyopathy, pressure overload).
• Evaluation of DWORF's structural features and regulatory interactions with SERCA2a and PLN.

Main Results:

• DWORF enhances SERCA2a activity by increasing catalytic turnover and displacing PLN.
• DWORF gene therapy improved Ca²⁺ handling, reduced fibrosis, and restored mitochondrial energetics in multiple preclinical HF models.
• DWORF's compact sequence is suitable for adeno-associated virus (AAV) delivery.

Conclusions:

• DWORF represents a mechanistically distinct and physiologically robust strategy for enhancing SERCA2a function in HF.
• DWORF gene therapy demonstrates significant therapeutic promise in preclinical studies.
• Further research is needed to address translational challenges, including species differences and safety, for clinical application.